Cancer Cells Are Vulnerable to Self-Destruction and Zombies

2019-02-28T16:40:23+00:00October 31st, 2018|Categories: Science|Tags: |

Ribonucleic acid (RNA) code is coming for you, cancer cells. A new Northwestern Medicine study reports that a kill code is embedded in every cell in the body whose function may be to cause the self-destruction of cells that become cancerous. As soon as the cell's inner bodyguards sense it is mutating into cancer, they [...]

Stem Cells, Jaw Bones, Salamanders and Medicine?

2018-09-09T04:38:50+00:00January 5th, 2017|Categories: Science|Tags: |

What do stem cells, jaw bones, and salamanders have in common? They all have played a part in the recent advancements in regenerative medicine. As the Mayo Clinic points out, regenerative medicine itself isn't new — forms of regenerative medicine such as the first bone marrow and solid-organ transplants were done decades ago. But advances [...]

Drone Delivery of Organ Transplants

2018-09-12T05:13:09+00:00May 3rd, 2016|Categories: Science|Tags: |

If you thought that drones could be used as a new way to deliver organ transplants, then you are thinking along the same lines as Lung Biotechnology. This month Lung Biotechnology has agreed to partner with aerial technology company EHang Holdings Limited to develop and purchase up to 1,000 units of the world's first autonomous [...]

J&J, Takeda and OrbiMed Incubator Aid Israel Fundraising

2018-09-20T04:05:13+00:00June 2nd, 2015|Categories: Science|Tags: |

  Johnson & Johnson (J&J), Takeda Pharmaceutical and venture capital firm OrbiMed have helped Israel break life science fundraising records through key investments such as establishing a biotech incubator. The biotech incubator, FutuRx, is the fruit of many months of work by Johnson & Johnson Innovation (the research development arm of J&J) along with Takeda [...]

FDA Clarifies Biosimilarity of Copycat Drugs

2014-06-05T09:00:49+00:00June 5th, 2014|Categories: Science|Tags: |

Up until last month, the Food and Drug Administration (FDA) has wavered on how it will regulate copycat drugs. Now, the FDA has made it more clear how it plans to define biosimilarity of copycat drugs being reviewed and the approved drugs they are trying to replace. In providing preliminary guidance, the FDA identified the following four categories of [...]

Go to Top